patients with such conditions deserve the same quality, safety and efficacy in medicinal products as other patients; orphan medicinal products should therefore be submitted to the normal evaluation process; sponsors of orphan medicinal products should have the possibility of obtaining a Community authorisation; in order to facilitate the granting or the maintenance of a Community authorisation, fees to be paid to the Agency should be waived at least in part; the Community budget should compensate the Agency for the loss in revenue thus occasioned;
Recital 7, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…
In forcesince 16 Dec 1999cited 1×
Judgment of the Court (Third Chamber) of 22 June 2023. Federal Republic of Germany v European Commission.Decision
Recital 7 of Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ 2000 L 18, p. 1) states: ‘ … orphan medicinal products should therefore be submitted to the …
22 Jun 2023 · 62021CJ0006